Trial Profile

Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Hydroxychloroquine; Lopinavir/ritonavir; Remdesivir
Indications COVID-19 pneumonia; Hypoxaemia; SARS-CoV-2 acute respiratory disease
Focus Biomarker; Therapeutic Use
Acronyms UHID-COVID19

10 Nov 2020 Status changed from not yet recruiting to recruiting.
05 Jun 2020 Planned End Date changed from 15 Apr 2021 to 15 May 2021.
05 Jun 2020 Planned initiation date changed from 16 Apr 2020 to 16 Jun 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com